期刊文献+

特立帕肽与阿仑膦酸钠对绝经后骨质疏松患者的疗效对比 被引量:3

下载PDF
导出
摘要 目的探讨应用特立帕肽和阿仑膦酸钠对绝经后妇女骨质疏松患者的疗效。方法选取85例伴随骨密度降低的绝经后妇女进行半年随访,将患者分为2组,特立帕肽组40例给予特立帕肽20μg皮下注射,每日1次;阿仑膦酸钠组45例给予口服阿仑膦酸钠10 mg,每日1次;疗程均为半年,于用药后第1、2、3、6个月时采静脉血进行血清骨钙素检测,并在第6个月采用双能X线骨密度测量仪进行股骨近端、腰椎BMD的测定。结果骨密度测量结果显示,与阿仑膦酸钠组相比较特立帕肽组患者其脊柱和股骨近端的骨密度明显增高[(19±10)%与(6±5)%,P<0.05],股骨颈的骨密度显著增高[(12±5)%与(4±3)%,P<0.05];特立帕肽组的血清骨钙素水平较阿仑膦酸钠组明显增高(P<0.05)。结论与阿仑膦酸钠相比较特立帕肽可明显提高绝经后妇女骨质疏松患者的骨密度,增高血清骨钙素水平。
出处 《宁夏医学杂志》 CAS 2015年第7期648-650,共3页 Ningxia Medical Journal
  • 相关文献

参考文献9

  • 1Cooper C, Jakob F, Chinn C, et al. Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy : the observational study of severe osteoporosis [ J]. Osteoporos Int,2008,19 (4) :493 - 501.
  • 2Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis:a systematic review and cost - utility analysis [ J ]. Health Teehnol Assess,2002,6(29) : 1.
  • 3施健,张健.阿仑膦酸钠的研究进展[J].武警医学,2008,19(2):177-179. 被引量:8
  • 4Delrm PD. Treatment of postmenopausal osteoporosis [ J ]. Lancet,2002,359:2018.
  • 5Fahrleitner A, Prenner G, Kniepeiss D, et al. Serum osteoprotegerim levels in patients after liver transplantation and correlation to bone turnover bone mineral density and fracture status [ J ]. Wien Klin Woehenschr,2002,114 (15/16) :717 - 724.
  • 6Harada S, Rodan CA. Control of oeteoblast function and regulation of bone mass~ J~. Nature ,2003,423 (6937) :349 - 355.
  • 7Anastasilakis AD, Goulis DG, Polyzos SA, et al. Head - to - head comparison of risedronatevs, teriparatide on bone tumovermarkers in women with postmenopausal osteopomsis : a randomized trial[ J]. IntJ Clin Pract,2008,62(6) :919 -924.
  • 8Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid - induced osteoporosis [ J ]. N Engl J Med,2007,357 (20) :2028 - 2039.
  • 9Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of para- thyroid hormone, alendronate, or both in men with osteoporosis [ J ]. N Engl J Med,2003 ,349(13) :1216 - 1226.

二级参考文献22

  • 1Delmas PD. Treatment of postmenopausal osteoporosis. Lancet, 2002, 359(9 322) :2 018
  • 2Sambrook PN. Glueocorticoid osteoporosis. Curt Pharm Des, 2002, 8 (21):1 877
  • 3Smith MR, Antiturmor activity of bisphosphonates. Clin Cancer Res, 2003,9(15) :5 433
  • 4Frith JC, Rogers MJ. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miller Res, 2003,18:204
  • 5Catterall JB, Cawston TE. Drugs in development: bisphosphonates and metaUoproteinase ibhibitors. Arthritis Res Ther, 2003,5 ( 1 ) : 12
  • 6Etienne- Manneville S, Hall A. Rho GTPases in cell biology. Nature, 2002,420:629
  • 7Coxon FP, Rogers MJ. The role of prenylated small GTP - binding proteins in the regulation of osteoclast function. Calcify Tissue Int, 2003, 72:80
  • 8Taggart H, Bolognese MA, Lindsay R et al . Upper gastrointestinal tract safety of risedronate:a pooled analysis of 9 clinical trials, Mayo Clin Proc, 2002,77:262
  • 9Lehekari PP, Kellinsalmi M, Napankangas JP. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ ATP translocase by a nonhydrolyzable, adenine - containing metabolite. Mol Pharmacol,2002,61:1 255
  • 10Viereck V, Emons G, Lauck Vet al . Bisphosphonates pamidronate and zoledronlc acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun, 2002,291 (3) : 680

共引文献7

同被引文献17

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部